Clinical Trial Technologies for Improving Equity and Inclusion in Cardiovascular Clinical Research
Approximately one-third of clinical trials fail to meet their recruitment goals, which can cause costly delays to sponsors and compromise the scientific integrity and generalizability of a trial. Inadequate recruitment and retention of patient groups who have the disease under investigation may prod...
Saved in:
Published in | Cardiology and Therapy Vol. 12; no. 2; pp. 215 - 225 |
---|---|
Main Authors | , , |
Format | Journal Article |
Language | English |
Published |
Cheshire
Springer Healthcare
01.06.2023
Springer Adis, Springer Healthcare |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Approximately one-third of clinical trials fail to meet their recruitment goals, which can cause costly delays to sponsors and compromise the scientific integrity and generalizability of a trial. Inadequate recruitment and retention of patient groups who have the disease under investigation may produce insufficient medical knowledge about the therapeutic effects of drugs or products for the population at large. It is essential to address these issues to ensure that certain groups are not unduly subjected to disproportionate risks or denied the benefits of research. This commentary will present opportunities for clinical trialists to use emerging technologies and decentralized approaches to improve clinical trial recruitment, mitigate disparities, and improve individual and population-level outcomes within cardiovascular medicine. |
---|---|
Bibliography: | SourceType-Other Sources-1 content type line 63 ObjectType-Correspondence-1 |
ISSN: | 2193-8261 2193-6544 |
DOI: | 10.1007/s40119-023-00311-y |